Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup

Journal of Urology

Volumn 164, Issue 5, 2000, Pages 1579-1582

  Iversen, Peter ^b   Tyrrell, Chris J ^b   Kaisary, Amir V ^b   Anderson, John B ^b   Van Poppel, Hein ^b   Tammela, Teuvo L J ^b   Chamberlain, Michael ^b   Carroll, Kevin ^b   Melezinek, Ivan ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NONE

Author keywords

Androgen antagonists; Orchiectomy; Prostate; Prostatic neoplasms

Indexed keywords

BICALUTAMIDE; GOSERELIN;

ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; GYNECOMASTIA; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MALE; MASTALGIA; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEXUAL FUNCTION;

EID: 0033782359     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67032-2     Document Type: Article

References (20)

1. Cancer statistics, 1999
2. Treatment options for early prostate cancer
3. Patients' choice of treatment in stage D prostate cancer
4. Assessment of quality of life in patients with prostate cancer
5. Quality of life, sexual functioning and sex role identity after surgical orchidectomy in patients with prostatic cancer
6. Progressive osteoporosis during androgen deprivation therapy for prostate cancer
7. Sexual functioning in testosterone-supplemented patients treated for bilateral testicular cancer
8. Management of male osteoporosis: Report of the UK Consensus Group
9. Testosterone deficiency as a risk factor for hip fractures in men: A case-control study
10. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer
11. Bicalutamide dosages used in the treatment of prostate cancer
12. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: Results of an Italian Prostate Cancer Project study
13. French multicentre trial comparing Casodex (ICI 176,334) monotherapy with castration plus nilutamide in metastatic prostate cancer: A preliminary report
14. Bicalutamide (Casodex®) versus combined androgen blockade (CAB): Open French multicentre study in patients with metastatic prostate cancer
15. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer
16. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: Results from two multicenter randomized trials at a median follow-up of 4 years
17. Health-related quality of life in patients with advanced prostate cancer: A multinational perspective
18. Quality of life issues relating to endocrine treatment options
19. Patient preferences: Survival vs quality-of-life considerations
20. Gynaecomastia: Aetiology and treatment options